As mentioned in the previous section, carbapenems possess a variety of methods to resist enzymatic degradation by DHP-1 or from β-lactamases. Additionally, these antibiotics have slight variability in target site binding affinity, efflux pump susceptibility, and the ability to pass through porin channels. These factors contribute to slightly different spectrums of activity in relatively similar antibiotics.
Tebipenem has a broad spectrum of activity against gram-negative and gram-positive organisms. Early studies of the prodrug and active metabolite were conducted in Japan in the late 90 s to evaluate in vivo and in vitro activity. These studies found that tebipenem had in vitro activity against methicillin-sensitive
Staphylococcus aureus, penicillin-sensitive and resistant
Streptococcus pneumoniae, and
Streptococcus pyogenes [
12,
13]. For these gram-positive organisms, tebipenem has variable binding affinity for different PBPs. In
S. aureus isolates, tebipenem will bind to all PBPs but had a lower affinity for PBP2 and PBP3, and little to no activity for PBP2a [
14•]. In
S. pneumoniae, tebipenem has been shown to have binding affinity for PBP1a, PBP1b, PBP2a, PBP2b, and PBP3 [
12]. Based on these binding affinities, the MIC
90 values for MSSA range from 0.025 to 0.125 mg/L, MRSA from 12.5 to 16 mg/L, and
S. pyogenes between ≤ 0.006 and ≤ 0.125 [
12,
14•,
15]. Importantly, these studies also demonstrated a lack of activity against
Enterococcus faecium,
Acinetobacter baumannii, and
Pseudomonas aeruginosa similar to the activity of ertapenem (Table
1). For other gram-negative organisms, tebipenem has affinity for several PBPs. In
E. coli and
K. pneumoniae, tebipenem had high affinity for PBP2 and moderate affinity for PBP1a, PBP1b, and PBP3 [
14•]. To compare the spectrum of this new agent to commercially available products, an in vitro analysis was conducted with
E coli,
K. pneumoniae, and
P. mirabilis isolates. For
E. coli, tebipenem had MIC
50/90 values of ≤ 0.015/0.03 mg/L which were equivalent to the MICs shown for ertapenem and meropenem and 8 times lower than the MICs seen for imipenem. In
K. pneumoniae isolates, tebipenem MIC
50/90 were 0.03/0.06 mg/L which were the same seen in meropenem, 4–8 times lower than the MICs seen for imipenem, and MIC
50/90 for ertapenem were reported at ≤ 0.015/0.25 mg/L. The last comparative organism was
P. mirabilis which tebipenem demonstrated MIC
50/90 of 0.06/0.12 mg/L the same as meropenem, 4–8 times lower than MIC
50/90 seen for doripenem, but higher than MIC
50/90 seen for ertapenem (≤ 0.015/ ≤ 0.015). The study went on to compare the activity of tebipenem in ESBL- and AmpC-producing isolates of
E coli,
K. pneumoniae, and
P. mirabilis. When used in presence of these enzymes, tebipenem MIC
50 remained stable at 0.03 mg/L, while MIC
90 had a slight increase to 0.25 mg/L [
16]. In vitro studies have also evaluated tebipenem as a potential treatment option for
Mycobacterium infections. One study evaluated the activity of carbapenems alone and in combination with either isoniazid, rifampin, or clavulanic acid against
M. tuberculosis and
M. abscessus. When used alone, tebipenem had the highest in vitro potency (MIC
90 = 1.25–2.5 mg/L) against
M. tuberculosis compared to faropenem, biapenem, doripenem, peropenem, ertapenem, imipenem, and panipenem. When combined with clavulanic acid, the MIC
90 of tebipenem was reduced to 0.31–0.62 mg/L. However, tebipenem was much less active against
M. abscessus isolates with MIC
90 ranging from 40 to 80 mg/L. The effects of rifampin and isoniazid combination therapy were not evaluated with tebipenem [
17].
Table 1
MIC
50 and MIC
90 ranges noted in studies evaluating activity against microorganism with comparison against meropenem and ertapenem when available [
11‐
13,
15,
18,
19]
MSSA | 0.025 to ≤ 0.125 | 0.025–0.125 | 0.06–0.1 | 0.1–0.12 | 0.12 to ≤ 0.125 | 0.25 | 0.12 | 0.25 |
MRSA | 6.25–18 | 12.5–16 | 12.5–16 | 64–100 | 8–16 | 16–32 | 4 | 32 |
MSSE | ≤ 0.03–0.1 | 0.125–0.5 | | | ≤ 0.125 | 1 | 0.25 | 0.25 |
MRSE | 2–8 | 6.25–8 | | | 16 | 16 | | |
S. pneumonia | 0.002 to ≤ 0.006 | ≤ 0.006–0.032 | ≤ 0.006–0.008 | 0.06–0.1 | ≤ 0.016 | 0.016 | 0.016 | 0.016 |
S. pyogenes | ≤ 0.006 to ≤ 0.125 | ≤ 0.006 to ≤ 0.125 | 0.012–0.03 | 0.025–0.03 | ≤ 0.125 | ≤ 0.125 | ≤ 0.016 | ≤ 0.016 |
E. faecalis | 0.25–0.5 | 2–32 | 3.13–4 | 6.25–8 | 2–8 | 8 to > 128 | 8 | 16 |
E. faecium | 64 | 128 | | | > 128 | > 128 | | |
E. coli | ≤ 0.025– ≤ 0.125 | 0.05–1 | 0.025–0.03 | 0.03–0.06 | 0.03 to ≤ 0.125 | 0.03–1 | 0.008 | 0.03 |
H. influenzae | 0.05– ≤ 0.125 | 0.25–0.39 | 0.2–0.25 | 0.2–0.25 | 0.06 to ≤ 0.125 | 0.12–0.5 | 0.06 | 0.12 |
K. pneumoniae | ≤ 0.025– ≤ 0.125 | 0.05–0.5 | 0.025–0.03 | 0.05–0.12 | 0.03 to ≤ 0.125 | 0.03–1 | 0.008 | 0.06 |
M. catarrhalis | 0.025 to ≤ 0.063 | 0.05 to ≤ 0.063 | 0.03 | 0.12 | 0.08 | 0.08 | 0.008 | 0.016 |
E. cloacae | 0.05 to ≤ 0.125 | 0.2–1 | 0.12–0.2 | 0.5–0.78 | 0.06 to ≤ 0.125 | 0.12–2 | ≤ 0.06 | 0.5 |
P. mirabilis | ≤ 0.125–0.39 | ≤ 0.125–0.39 | 0.1–0.25 | 0.2–0.5 | 0.06 to ≤ 0.125 | 0.12–0.5 | 0.016 | 0.03 |
S. marcescens | ≤ 0.125–0.39 | 16–25 | 0.5–0.78 | 2–50 | 0.12 to ≤ 0.125 | 0.25–32 | 0.03 | 0.12 |
P. aeruginosa | 6.25–8 | 64–100 | 25–32 | > 64–100 | 0.5–2 | 4–32 | 8 | 8 |
A. baumannii | 16 | 24 | 0.5 | 1 | 32 | 64 | 4 | > 8 |
S. maltophilia | 62 | 64 | 100–128 | > 100 to > 128 | 62 | 128 | > 8 | > 8 |
Sulopenem demonstrates a comparable spectrum of activity to those of tebipenem and ertapenem. Early studies showed that sulopenem binds to PBP2, PBP1a, PBP1b, PBP4, and PBP5 in order from highest to lowest binding affinity and has demonstrated in vitro activity against
S. pneumoniae,
E. faecalis,
Listeria monocytogenes, MSSA, and
Staphylococcus epidermidis [
11]. Similar with tebipenem, sulopenem MIC
90 against MSSA ranged from 0.10 to 0.12 mg/L, while MRSA values ranged from 64 to 100 mg/L. The elevated MIC values for MRSA isolates can be explained by the fact that sulopenem has a much lower binding affinity for PBP2A that is present in the resistant organism. A more recent study evaluated the activity of sulopenem against 1647 Enterobacterales and 559 anaerobic isolates. This study demonstrated in vitro activity against all isolates tested. Activity was maintained against ESBL-producing Enterobacteriaceae with MIC
90 values for sulopenem only increasing from 0.06 to 1 in
K. pneumoniae and from 0.03 to 0.06 in
E. coli in the presence of ESBL. Unsurprisingly, sulopenem lacks activity against carbapenem-resistant strains, with the MIC
50 of
K. pneumoniae increasing from 0.03 to 16 when carbapenem resistance was noted [
18]. Similar to ertapenem, sulopenem lacks activity against
Pseudomonas aeruginosa [
19]. This is believed to be due to the poor affinity of sulopenem for PBB5, one of the predominant proteins in
P. aeruginosa. Compared to currently available carbapenems, sulopenem has a similar in vitro potency. In
E. coli isolates, sulopenem MIC
50/90 has been 0.03/0.06 mg/L which was comparable to ertapenem and meropenem, but lower than imipenem values (0.008/0.03 mg/L, 0.03/0.03 mg/L, and 0.25/0.25 mg/L, respectively). Among
Klebsiella spp., only meropenem had a lower MIC
90 than sulopenem (0.06 vs 0.12). While sulopenem demonstrates greater activity against
Acinetobacter spp. than ertapenem, as evident by the decrease in MIC
50 from 4 to 0.5 mg/L, it is still not as potent as either meropenem or imipenem which both have MIC
50 values of 0.25 mg/L.
While both new agents have broad spectrums of activity, there are a few notable exclusions. Like other carbapenems, neither of these agents have activity against methicillin-resistant Staphylococcus aureus or carbapenem-resistant Enterobacteriaceae. Similar to ertapenem, neither has appreciable coverage against Pseudomonas or Enterococcus. Unlike tebipenem, sulopenem does have some activity against Acinetobacter spp. But considering other available carbapenems are more potent, neither agent is likely to become a first-line option for those infections. For the organisms that these new agents have demonstrated activity against, it is important to note that many of these tests were conducted in vitro or murine models, and there are currently no FDA, CLSI, or EUCAST breakpoints available for either agent.